| Literature DB >> 30305231 |
Erika A Newman1, Shahab Abdessalam2, Jennifer H Aldrink3, Mary Austin4, Todd E Heaton5, Jennifer Bruny6, Peter Ehrlich7, Roshni Dasgupta8, Reto M Baertschiger9, Timothy B Lautz10, Daniel S Rhee11, Max R Langham12, Marcus M Malek13, Rebecka L Meyers14, Jaimie D Nathan8, Brent R Weil15, Stephanie Polites8, Mary Beth Madonna10.
Abstract
Neuroblastoma is an embryonic cancer arising from neural crest stem cells. This cancer is the most common malignancy in infants and the most common extracranial solid tumor in children. The clinical course may be highly variable with the possibility of spontaneous regression in the youngest patients and increased risk of aggressive disease in older children. Clinical heterogeneity is a consequence of the diverse biologic characteristics that determine patient risk and survival. This review will focus on current progress in neuroblastoma staging, risk stratification, and treatment strategies based on advancing knowledge in tumor biology and genetic characterization. TYPE OF STUDY: Review article. LEVEL OF EVIDENCE: Level II.Entities:
Keywords: Cancer; Neuroblastoma; Oncology; Solid tumor; Surgery; Treatment
Mesh：
Year: 2018 PMID： 30305231 DOI： 10.1016/j.jpedsurg.2018.09.004
Source DB: PubMed Journal: J Pediatr Surg ISSN： 0022-3468 Impact factor: 2.545